Chemical Information
Antiviral agent ID	DrugRepV_3745
Antiviral agent name	Falnidamol
IUPAC Name	4-N-(3-chloro-4-fluorophenyl)-6-N-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-4,6-diamine
SMILES (canonical)	CN1CCC(CC1)NC2=NC=C3C(=N2)C(=NC=N3)NC4=CC(=C(C=C4)F)Cl
Molecular Formula	C18H19ClFN7
Molecular Weight (g/mol)	387.847
InChl	InChI=1S/C18H19ClFN7/c1-27-6-4-11(5-7-27)25-18-21-9-15-16(26-18)17(23-10-22-15)24-12-2-3-14(20)13(19)8-12/h2-3,8-11H,4-7H2,1H3,(H,21,25,26)(H,22,23,24)
Common Name	Falnidamol
Structural Information
Clinical Information
Primary Indication (Clinical trial phases)	Investigational
Biological Information
Primary Indication (Disease Category)	Non Infectious Disease
Primary Indication (Disease)	Solid Tumor
Secondary Indication	Ebola virus (EBOV) NA 1976
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Model system) [cell lines/ animal models]	A549
Secondary Indication (Mode of drug delivery)	Culture
Secondary Indication (Time of drug delivery)	Post infection
Secondary Indication (Duration of drug delivery)	72 hours
Secondary Indication (Drug concentration)	1.2 ± 0.2 μM
Secondary Indication (Cell based assay)	Firefly luciferase assay
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	EC50 [ 50 % ]
Secondary Indication (Cytotoxicity)	24.3 ± 3.9 μM
Reference	Mohr EL, McMullan LK, Lo MK, Spengler JR, Bergeron E, Albarino CG, Shrivastava-Ranjan P, Chiang CF, Nichol ST, Spiropoulou CF, Flint M..Inhibitors of cellular kinases with broad-spectrum antiviral activity for hemorrhagic fever viruses..Antiviral Res. 2015 Aug;120:40-7. doi: 10.1016/j.antiviral.2015.05.003. Epub 2015 May 16. PMID:25986249
Comment	BIBX 1382 is an inhibitor of LASV and EBOV entry. OSU-03012 reduces LASV and EBOV virus titers and RNA levels, but does not inhibit entry or LASV Z-protein mediated assembly.